<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OPP</journal-id>
<journal-id journal-id-type="hwp">spopp</journal-id>
<journal-id journal-id-type="nlm-ta">J Oncol Pharm Pract</journal-id>
<journal-title>Journal of Oncology Pharmacy Practice</journal-title>
<issn pub-type="ppub">1078-1552</issn>
<issn pub-type="epub">1477-092X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1078155212459285</article-id>
<article-id pub-id-type="publisher-id">10.1177_1078155212459285</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Ifosfamide-induced neurotoxicity reversal with continuous veno-venous hemodialysis. A case report</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Cherry</surname><given-names>Mohamad A</given-names></name>
</contrib>
<aff id="aff1-1078155212459285">Department of Medicine, Hematology Oncology Section, Oklahoma University, OK, USA</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Bhardwaj</surname><given-names>Himanshu</given-names></name>
</contrib>
<aff id="aff2-1078155212459285">Department of Medicine, Oklahoma University, OK, USA</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Hopps</surname><given-names>Sarah</given-names></name>
</contrib>
<aff id="aff3-1078155212459285">Department of Pharmacy, Oklahoma University, OK, USA</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Srour</surname><given-names>Samer</given-names></name>
</contrib>
<aff id="aff4-1078155212459285">Department of Medicine, Hematology Oncology Section, Oklahoma University, OK, USA</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Pant</surname><given-names>Shubham</given-names></name>
<xref ref-type="corresp" rid="corresp1-1078155212459285"/>
</contrib>
<aff id="aff5-1078155212459285">Department of Medicine, Hematology Oncology Section, Oklahoma University, OK, USA</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1078155212459285">Shubham Pant, Department of Medicine, Hematology Oncology Section, Oklahoma University, 920 Stanton L Young Blvd, Oklahoma City, OK 73104, USA. Email: <email>shubam-pant@ouhsc.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>3</issue>
<fpage>261</fpage>
<lpage>264</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Ifosfamide is an alkylating agent used to treat different types of malignancies including lymphomas, sarcomas and germinal cell tumors. Symptoms of ifosfamide neurotoxicity can range from mild confusion, dizziness and hallucination to overt encephalopathy. Various treatment options like methylene blue, albumin infusion and rarely hemodialysis have been used to treat ifosfamide neurotoxicity. We hereby report a case of a patient with relapsed diffuse large B cell lymphoma who received methylene blue after experiencing acute renal failure and encephalopathy due to ifosfamide with no improvement. The prompt use of hemodialysis in this case has led to reversal of both renal failure and neurotoxicity.</p>
</abstract>
<kwd-group>
<kwd>Ifosfamide neurotoxicity and nephrotoxicity</kwd>
<kwd>chemotherapy side effects</kwd>
<kwd>hemodialysis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-1078155212459285" sec-type="intro"><title>Introduction</title>
<p>Ifosfamide is an alkylating agent and analog of cyclophosphamide. It has wide applications in treating lymphomas and solid tumor (sarcomas and germinal cell tumors). Neurotoxicity is one of the worrisome complications that occur in up to 40% of cases. Prompt diagnosis with discontinuation of ifosfamide and use of methylene blue are essential in treating this condition. Despite these measures, a minority of patients with severe ifosfamide-induced neurotoxicity will not respond to such approach leading to a fatal outcome in rare circumstances.</p>
</sec>
<sec id="sec2-1078155212459285" sec-type="cases"><title>Case report</title>
<p>A 67-year-old Caucasian gentleman was seen at the oncology clinic for increased left lower extremity swelling. Two weeks earlier, the patient was evaluated by a local emergency room (ER) physician and an ultrasound of the lower extremity showed no evidence of deep vein thrombosis. This was followed by an MRI of the lower extremity, which showed possible malignant infiltration of the dermis and the quadriceps muscle. A skin biopsy was performed and was consistent with recurrent diffuse large B cell lymphoma (DLBCL). The location and dermis involvement was suggestive of the diagnosis of primary cutaneous DLBCL of leg type. One year earlier, the patient was diagnosed with DLBCL involving the right hip and pelvis. He achieved complete remission after taking six cycles of combination chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP).</p>
<p>In the clinic, the patient reported increasing pain in his left thigh over the last 2 weeks before presentation. He could only walk using crutches. He denied any fever, chills, night sweats, weight loss, decrease appetite, chest pain, shortness of breath, nausea, vomiting, diarrhea or any other symptoms. On examination, the patient appeared relatively well. He was afebrile and his vital signs were unremarkable. There was no palpable lymphadenopathy. His thigh was swollen and tender to touch. The left thigh was at least twice the size of the right one. The rest of the exam was normal. The patient was admitted to the hospital for salvage chemotherapy. His CBC showed a WBC of 11.2 × 10 E9/L (normal differential). Hemoglobin of 11.5 g/dL and platelet count of 169 × 10 E9/L. His serum creatinine was 1.57 g/dL and his lactate dehydrogenase of 592 units/L (normal: 90–190 units/L). The bone marrow and cerebrospinal fluid examination (CSF) showed no evidence of malignancy. A PET-CAT scan showed diffused FDG uptake within the soft tissue of the anterior left thigh only. The decision was made to start rituximab, ifosfamide, carboplatin and etoposide (R-ICE) regimen, and the schedule was determined on the basis of body surface area (2.3 m<sup>2</sup>) with 860 mg of rituximab infused slowly over 5 to 6 h on day 1, ifosfamide 11.5 g infused over 24 h on day 2, etoposide 229 mg infused over 60 min on days 1 to 3, and carboplatin 443 mg infused over 60 min on day 2. Within few hours of completion of the first dose of ifosfamide infusion, the patient became disoriented but still was able to recognize his family members. Ifosfamide-induced neurotoxicity was suspected and methylene blue was initiated intravenously at 50 mg every 8 h. The rest of chemotherapeutic agents were not given. The following day, the patient became more confused and somnolent. He was arousable with deep stimulation such as sternal rubs. Neurology team was consulted and CT, MRI brain and CSF testing were done and were unremarkable. In addition, patient developed as well progressive acute renal failure (ARF) with increase of his serum creatinine to 3.5 mg/dL. One day later, his mental status continued to deteriorate, and he became comatose and was transferred to the intensive care unit (ICU). Continuous veno-venous hemodialysis (CVVHD) was initiated. The patient showed dramatic improvement and within couple of days his encephalopathy and ARF (creatinine 1.54 g/dL) resolved. Of note, the patient had remarkable response to chemotherapy with significant decrease in the thigh swelling.</p>
</sec>
<sec id="sec3-1078155212459285" sec-type="discussion"><title>Discussion</title>
<p>Ifosfamide, an oxazaphosphorine alkylating agent, is an isomeric analog of cyclophosphamide.<sup><xref ref-type="bibr" rid="bibr1-1078155212459285">1</xref></sup> Encephalopathy occurs in 10–40% of patients receiving high-doses. Ifosfamide is a prodrug that is metabolized in the liver by the cytochrome P450 system to its active metabolite, 4-hydroxyifosfamide. In contrast to cyclophosphamide, ifosfamide is dechloroethylated to chloroacetaldehyde, the metabolite that is thought to be associated with neurotoxicity.<sup><xref ref-type="bibr" rid="bibr2-1078155212459285">2</xref></sup> Blood concentrations of this metabolite have been shown to be higher in patients with neurotoxicity.<sup><xref ref-type="bibr" rid="bibr3-1078155212459285">3</xref></sup> There is a clear dose-toxicity relationship.<sup><xref ref-type="bibr" rid="bibr4-1078155212459285">4</xref></sup></p>
<p>Encephalopathy can develop between 12 and 146 h after administration of ifosfamide.<sup><xref ref-type="bibr" rid="bibr5-1078155212459285">5</xref><xref ref-type="bibr" rid="bibr6-1078155212459285"/><xref ref-type="bibr" rid="bibr7-1078155212459285"/>–<xref ref-type="bibr" rid="bibr8-1078155212459285">8</xref></sup> Symptoms of neurotoxicity include confusion, extrapyradmidal symptoms, seizure and hallucinations and can lead to coma and death.<sup><xref ref-type="bibr" rid="bibr9-1078155212459285">9</xref>,<xref ref-type="bibr" rid="bibr10-1078155212459285">10</xref></sup> Spontaneous resolution of encephalopathy can occur 48 to 72 h after discontinuation of ifosfamide,<sup><xref ref-type="bibr" rid="bibr2-1078155212459285">2</xref>,<xref ref-type="bibr" rid="bibr8-1078155212459285">8</xref></sup> however it can persist for a prolonged period of time.<sup><xref ref-type="bibr" rid="bibr5-1078155212459285">5</xref>,<xref ref-type="bibr" rid="bibr7-1078155212459285">7</xref></sup></p>
<p>Treatment of neurotoxicity involves discontinuing ifosfamide, supportive care with haloperidol or benzodiazepines and electroencephalographic monitoring.<sup><xref ref-type="bibr" rid="bibr11-1078155212459285">11</xref>,<xref ref-type="bibr" rid="bibr12-1078155212459285">12</xref></sup> Methylene blue has also been used to treat and prevent neurotoxicity.<sup><xref ref-type="bibr" rid="bibr5-1078155212459285">5</xref>,<xref ref-type="bibr" rid="bibr9-1078155212459285">9</xref>,<xref ref-type="bibr" rid="bibr12-1078155212459285">12</xref></sup> When compared to placebo, it has been shown to lower the occurrence of neurotoxicity.<sup><xref ref-type="bibr" rid="bibr13-1078155212459285">13</xref></sup> One case report, in a patient receiving ifosfamide 2 g/m<sup>2</sup>, showed improvement ifosfamide-induced encephalopathy after 2 h of methylene blue administration.<sup><xref ref-type="bibr" rid="bibr10-1078155212459285">10</xref></sup> A retrospective cohort study analyzed 19 patients that received methylene blue prophylactically along with high-dose ifosfamide (median dose 2 g/m<sup>2</sup>) showed that 8 of them developed encephalopathy.<sup><xref ref-type="bibr" rid="bibr14-1078155212459285">14</xref></sup> Five of the eight patients also received treatment with methylene blue with resolution of symptoms in 48–72 h.</p>
<p>A recent retrospective analysis compared the use of albumin for prophylaxis in 41 patients who received ifosfamide for the treatment of hematologic malignancy or solid tumor. Neurotoxicity was more common in the albumin group compared with no albumin; therefore, prophylactic albumin was not effective in preventing neurotoxicity.<sup><xref ref-type="bibr" rid="bibr15-1078155212459285">15</xref></sup></p>
<p>Chloracetaldehyde has been shown to accumulate in patients with renal insufficiency.<sup><xref ref-type="bibr" rid="bibr3-1078155212459285">3</xref>,<xref ref-type="bibr" rid="bibr11-1078155212459285">11</xref>,<xref ref-type="bibr" rid="bibr16-1078155212459285">16</xref></sup> In vitro studies suggest that hemodialysis can decrease ifosfamide concentrations by 87% and chloracetaldehyde by 77%.<sup><xref ref-type="bibr" rid="bibr17-1078155212459285">17</xref></sup> A case report of a patient, who mistakenly received a rapid infusion of 9 g of ifosfamide over 1 h, was given prophylactic hemodialysis and hemoperfusion, this decreased serum ifosfamide concentrations by 84% and the patient did not experience neurotoxicity.<sup><xref ref-type="bibr" rid="bibr18-1078155212459285">18</xref></sup> A case series of three patients reported that ifosfamide was safely given in patients with end-stage renal disease with concurrent dialysis with no reports of neurotoxicity.<sup><xref ref-type="bibr" rid="bibr16-1078155212459285">16</xref></sup></p>
<p><xref ref-type="table" rid="table1-1078155212459285">Table 1</xref> summarizes the previous published cases where dialysis was used in patients receiving high dose ifosfamide. To the best of our knowledge, our case is the first published one where a comatose patient (due to ifosfamide-induced neurotoxicity) completely recovered with CVVHD after failure to initial therapy with methylene blue.
<table-wrap id="table1-1078155212459285" position="float"><label>Table 1.</label><caption><p>Summary of published patients receiving dialysis after high dose ifosfamide.</p></caption>
<graphic alternate-form-of="table1-1078155212459285" xlink:href="10.1177_1078155212459285-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Diagnoses</th>
<th>Age/Gender (M/F)</th>
<th>Ifosfamide dose</th>
<th>Chemotherapy regimen</th>
<th>Neurotoxicity related symptoms</th>
<th>Outcome after dialysis</th>
<th>Comments</th>
</tr></thead>
<tbody align="left">
<tr>
<td align="justify">Relapsed NHL<sup>18</sup></td>
<td align="justify">38 y/M</td>
<td align="justify">5 g/m<sup>2</sup></td>
<td align="justify">ICE</td>
<td align="justify">Sight confusion and muscle weakness</td>
<td align="justify">Patient neurotoxicity and nephrotoxicity resolved</td>
<td align="justify">Hemoperfusion and Hemodialysis were combined. It took 10 days for the kidney function to recover</td>
</tr>
<tr>
<td align="justify">HG-SS<sup><xref ref-type="bibr" rid="bibr17-1078155212459285">17</xref></sup></td>
<td align="justify">48 y/M</td>
<td align="justify">2 g/m<sup>2</sup>, increased to 4 g/m<sup>2</sup></td>
<td align="justify">NA</td>
<td align="justify">No symptoms</td>
<td align="justify">Base line ESRD</td>
<td align="justify">Had good oncologic response</td>
</tr>
<tr>
<td align="justify">metastatic LS<sup><xref ref-type="bibr" rid="bibr17-1078155212459285">17</xref></sup></td>
<td align="justify">51 y/F</td>
<td align="justify">1.5 g/m<sup>2</sup>, increased to 2 g/m<sup>2</sup></td>
<td align="justify">NA</td>
<td align="justify">Mild peripheral neuropathy</td>
<td align="justify">Base line ESRD</td>
<td align="justify">Had good oncologic response</td>
</tr>
<tr>
<td align="justify">metastatic MRCLS<sup><xref ref-type="bibr" rid="bibr17-1078155212459285">17</xref></sup></td>
<td align="justify">67y/M</td>
<td align="justify">1.5 g/m<sup>2</sup>, increased to 1.8 g/m<sup>2</sup></td>
<td align="justify">AI</td>
<td align="justify">No symptoms</td>
<td align="justify">Base line ESRD</td>
<td align="justify">Had good oncologic response</td>
</tr>
<tr>
<td align="justify">Relapsed NHL (current study)</td>
<td align="justify">67y/M</td>
<td align="justify">5 g/m<sup>2</sup></td>
<td align="justify">R-ICE</td>
<td align="justify">Started with confusion, then progressed to coma</td>
<td align="justify">Patient neurotoxicity and nephrotoxicity resolved</td>
<td align="justify">Had good oncologic response. Kidney function recovered after 14 days</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1078155212459285">
<p>M/F: male/female; NHL: Non Hodgkin Lymphoma; ICE: ifosfamide, carboplatin and etoposide; HG-SS: high grade synovial sarcoma; ESRD: end-stage renal disease; LS: leiomyosarcoma; MRCLS: myxoid/round cell liposarcoma; AI: doxorubicin and ifosfamide; R-ICE: rituximab, ifosfamide, carboplatin and etoposide.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec4-1078155212459285" sec-type="conclusions"><title>Conclusion</title>
<p>Our case illustrates the successful use of CVVHD in patients with suspected ifosfamide nephrotoxicity and neurotoxicity who did not respond to methylene blue. The remarkable improvement of both the kidney function and neurosensorium in our patient supports the use of dialysis in such non-responding patients. In addition, early intervention with dialysis may potentially prevent neurotoxicity in patients at high risk with renal insufficiency. This should be studied on a larger scale in the future.</p>
</sec>
</body>
<back>
<sec id="sec5-1078155212459285"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<ref-list><title>References</title>
<ref id="bibr1-1078155212459285"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drings</surname><given-names>P</given-names></name><name><surname>Fritsch</surname><given-names>H</given-names></name></person-group>. <article-title>Erfahrungen mit iphosphamide in hoher Einzeldosis bei metastasierten soliden Tumoren</article-title>. <source>Verh Dtsch Ges Inn Medd</source> <year>1972</year>; <volume>78</volume>: <fpage>166</fpage>–<lpage>166</lpage></citation></ref>
<ref id="bibr2-1078155212459285"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kerbusch</surname><given-names>T</given-names></name><name><surname>d Kraker</surname><given-names>J</given-names></name><name><surname>Keizer</surname><given-names>HJ</given-names></name><etal/></person-group>. <article-title>Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolite</article-title>. <source>Clin Pharmacokinet</source> <year>2001</year>; <volume>40</volume>: <fpage>41</fpage>–<lpage>62</lpage></citation></ref>
<ref id="bibr3-1078155212459285"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goren</surname><given-names>MP</given-names></name><name><surname>Wright</surname><given-names>RK</given-names></name><name><surname>Pratt</surname><given-names>CB</given-names></name><etal/></person-group>. <article-title>Dechlorethylation of ifosfamide and neurotoxicity</article-title>. <source>Lancet</source> <year>1986</year>; <volume>2</volume>: <fpage>1219</fpage>–<lpage>1220</lpage></citation></ref>
<ref id="bibr4-1078155212459285"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meanwell</surname><given-names>CA</given-names></name><etal/></person-group>. <article-title>Prediction of ifosfamide/mesna associated encephalopathy</article-title>. <source>Eur J Cancer Clin Oncol</source> <year>1986</year>; <volume>22</volume>(<issue>7</issue>): <fpage>815</fpage>–<lpage>819</lpage>.</citation></ref>
<ref id="bibr5-1078155212459285"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Curtin</surname><given-names>JP</given-names></name><name><surname>Koonings</surname><given-names>PP</given-names></name><name><surname>Guitierrez</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Ifosfamide-induced neurotoxicity</article-title>. <source>Gynecol Oncol</source> <year>1991</year>; <volume>42</volume>: <fpage>193</fpage>–<lpage>196</lpage>.</citation></ref>
<ref id="bibr6-1078155212459285"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Merimsky</surname><given-names>O</given-names></name><name><surname>Reider-Groswasser</surname><given-names>I</given-names></name><name><surname>Wigler</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Encephalopathy in ifosfamide-treated patients</article-title>. <source>Acta Neurol Scand</source> <year>1992</year>; <volume>86</volume>: <fpage>521</fpage>–<lpage>525</lpage>.</citation></ref>
<ref id="bibr7-1078155212459285"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dimaggio</surname><given-names>JR</given-names></name><name><surname>Brown</surname><given-names>R</given-names></name><name><surname>Baile</surname><given-names>WF</given-names></name><etal/></person-group>. <article-title>Hallucinations and ifosfamide-induced neurotoxicity</article-title>. <source>Cancer</source> <year>1994</year>; <volume>73</volume>: <fpage>1509</fpage>–<lpage>1514</lpage>.</citation></ref>
<ref id="bibr8-1078155212459285"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nicolao</surname><given-names>P</given-names></name><name><surname>Giometto</surname><given-names>B</given-names></name></person-group>. <article-title>Neurological toxicity of ifosfamide</article-title>. <source>Oncology</source> <year>2003</year>; <volume>65</volume><supplement>Suppl 2</supplement><fpage>11</fpage>–<lpage>11</lpage>.</citation></ref>
<ref id="bibr9-1078155212459285"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pelgrims</surname><given-names>J</given-names></name><name><surname>De Vos</surname><given-names>F</given-names></name><name><surname>Van den Brande</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature</article-title>. <source>Br J Cancer</source> <year>2000</year>; <volume>82</volume>: <fpage>291</fpage>–<lpage>294</lpage>.</citation></ref>
<ref id="bibr10-1078155212459285"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alonso</surname><given-names>JL</given-names></name><etal/></person-group>. <article-title>Ifosfamide encephalopathy and methylene-blue: a case report</article-title>. <source>Ann Oncol</source> <year>1996</year>; <volume>7</volume>(<issue>6</issue>): <fpage>643</fpage>–<lpage>644</lpage>.</citation></ref>
<ref id="bibr11-1078155212459285"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meanwell</surname><given-names>CA</given-names></name><name><surname>Blake</surname><given-names>AE</given-names></name><name><surname>Kelly</surname><given-names>KA</given-names></name><etal/></person-group>. <article-title>Prediction of ifosfamide/mesna associated encephalopathy</article-title>. <source>Eur J Cancer Clin Oncol</source> <year>1986</year>; <volume>22</volume>: <fpage>815</fpage>–<lpage>819</lpage>.</citation></ref>
<ref id="bibr12-1078155212459285"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>P</given-names></name></person-group>. <article-title>Methylene blue for management of ifosfamide-induced encephalopathy</article-title>. <source>Ann Pharmacother</source> <year>2006</year>; <volume>40</volume>: <fpage>299</fpage>–<lpage>303</lpage>.</citation></ref>
<ref id="bibr13-1078155212459285"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kupfer</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue</article-title>. <source>Lancet</source> <year>1994</year>; <volume>343</volume>(<issue>8900</issue>): <fpage>763</fpage>–<lpage>764</lpage>.</citation></ref>
<ref id="bibr14-1078155212459285"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sweiss</surname><given-names>KI</given-names></name><name><surname>Beri</surname><given-names>R</given-names></name><name><surname>Shord</surname><given-names>SS</given-names></name></person-group>. <article-title>Encephalopathy after high-dose ifosfamide</article-title>. <source>Drug Safety</source> <year>2008</year>; <volume>31</volume>: <fpage>989</fpage>–<lpage>996</lpage>.</citation></ref>
<ref id="bibr15-1078155212459285"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kettle</surname><given-names>JK</given-names></name><etal/></person-group>. <article-title>Effectiveness of exogenous albumin administration for the prevention of Ifosfamide-induced encephalopathy</article-title>. <source>Pharmacotherapy</source> <year>2010</year>; <volume>30</volume>(<issue>8</issue>): <fpage>812</fpage>–<lpage>817</lpage>.</citation></ref>
<ref id="bibr16-1078155212459285"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Latcha</surname><given-names>S</given-names></name><name><surname>Maki</surname><given-names>RG</given-names></name><name><surname>Schwartz</surname><given-names>GK</given-names></name><etal/></person-group>. <article-title>Ifosfamide may be safely used in patients with end stage renal disease on hemodialysis</article-title>. <source>Sarcoma</source> <year>2009</year>; <volume>2009</volume>: <fpage>1</fpage>–<lpage>5</lpage>.</citation></ref>
<ref id="bibr17-1078155212459285"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sauer</surname><given-names>H</given-names></name><name><surname>Fuger</surname><given-names>K</given-names></name><name><surname>Blumenstein</surname><given-names>M</given-names></name></person-group>. <article-title>Modulation of cytotoxicity of cytostatic drugs by hemodialysis in vitro and in vivo</article-title>. <source>Cancer Treat Rev</source> <year>1990</year>; <volume>17</volume>: <fpage>293</fpage>–<lpage>300</lpage>.</citation></ref>
<ref id="bibr18-1078155212459285"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fiedler</surname><given-names>R</given-names></name><name><surname>Baumann</surname><given-names>F</given-names></name><name><surname>Deschler</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Haemoperfusion combined with haemodialysis in ifosfamide intoxication</article-title>. <source>Nephrol Dial Transplant</source> <year>2001</year>; <volume>16</volume>: <fpage>1088</fpage>–<lpage>1089</lpage>.</citation></ref>
</ref-list>
</back>
</article>